Coloplast A/S (OTCMKTS:CLPBY) Raised to “Strong-Buy” at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Coloplast A/S (OTCMKTS:CLPBY) from a hold rating to a strong-buy rating in a research note released on Tuesday,Zacks.com reports.

Several other research analysts have also recently weighed in on CLPBY. UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th. Hsbc Global Res raised shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th.

Coloplast A/S Price Performance

OTCMKTS CLPBY opened at $11.59 on Tuesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.02 and a quick ratio of 0.66. The business has a 50 day simple moving average of $11.54 and a 200 day simple moving average of $12.61. Coloplast A/S has a 52-week low of $10.63 and a 52-week high of $14.34.

Coloplast A/S (OTCMKTS:CLPBY) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter. The company had revenue of $1.02 billion during the quarter. Coloplast A/S had a net margin of 18.69% and a return on equity of 30.19%. As a group, analysts forecast that Coloplast A/S will post 0.36 EPS for the current fiscal year.

Coloplast A/S Increases Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 20th. Stockholders of record on Monday, December 9th were paid a dividend of $0.2435 per share. This is an increase from Coloplast A/S’s previous dividend of $0.05. The ex-dividend date of this dividend was Monday, December 9th. Coloplast A/S’s dividend payout ratio is currently 90.91%.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.